InvestorsHub Logo
Followers 27
Posts 676
Boards Moderated 0
Alias Born 07/26/2017

Re: Doc logic post# 211765

Friday, 02/01/2019 3:17:53 PM

Friday, February 01, 2019 3:17:53 PM

Post# of 699558
My belief has always been that NWBO chose to continue the trial against FDA recommendation because they wanted to make sure that they could establish a long survival to meet the QALY figures to be approved in every jurisdiction the world over.
If there had been any conflict of interest at all with whoever was overseeing the data then I am sure an early reveal would have hurt NWBO's chances of being seen as a clear winner in the immuno space as they would never be able to prove long term survival figures. This early unblinding may have given them ability to treat patients in the US but probably not in Europe/UK and other areas confined to universal health care cost constraints.
Early unblinding would allow the competition to leap frog NWBO tech within years and most definitely would have suited BP. Why have the shorts bleated for so long to unblind.
LP's assertion that we already had a home run I believe related to PFS, the additional home run is OS and it's impact will be far greater than PFS alone would ever have had.
I am looking forward to the big reveal and I believe LP has played her cards perfectly as DCVAX-L will now be available to millions more people than it would have been had NWBO followed FDA advice to unblind early.
Any noise between now and Topline is just mindless chatter.
To the shorts and detractors on this board, the game is over for you and all will be revealed in short order. Stay Tuned.
Too longs attending the ASM, keep it professional, we have been shown a path of breadcrumbs for many years and they lead to a very good space for cancer sufferers the world over.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News